Pfizer’s (NYSE: [[ticker:PFE]]) investigational compound, tafamidis, slowed the progression of a rare and fatal neurodegenerative disease over 30 months, according to a press release. The disease, called Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP), affects about 8,000 people worldwide. The data came from a late-stage clinical trial of the drug and was presented at the Annual Meeting of the Academy of Neurology on April 12. A week earlier, the FDA indicated that Pfizer would need to provide additional information to support its filing for approval for tafamidis, and the company indicated it was working with the agency to resolve that issue. The company also announced that an advisory panel to the FDA voted that the company’s cancer drug Sutent shows a favorable benefit-risk profile for the treatment of unresectable pancreatic neuroendocrine tumors. The vote brings the New York-based drug giant a step closer to being able to expand the label for Sutent, which is currently approved to treat some stomach and kidney cancers.
